Talis Biomedical Corporation (TLIS)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Talis Biomedical Corporation (TLIS) is up 0.0% since the beginning of the year. At $3 per share, TLIS is currently trading at its 52-week high. Investors who bought $1,000 worth of TLIS shares 5 years ago would now be looking at an investment worth $18.

Talis Biomedical Corporation (TLIS) has returned 0.00% so far this year and 98.60% over the past 12 months.

Based on dividend-adjusted daily data since Feb 12, 2021, TLIS's average daily return is -0.23%, while the average monthly return is -5.32%.

Historically, 29% of months were positive and 71% were negative. The best month was Dec 2025 with a return of +77.5%, while the worst month was Sep 2024 at -57.8%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 10 months.

On a daily basis, TLIS closed higher 35% of trading days. The best single day was Dec 18, 2025 with a return of +77.5%, while the worst single day was Sep 4, 2024 at -63.4%.

Talis Biomedical Corporation has an annualized alpha of -49.44%, beta of 0.66, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since February 16, 2021.

• This stock participated in 198.32% of S&P 500 Index downside but only -91.02% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.66 may look defensive, but with R2 of 0.02 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

TLIS ranks 89 for risk / return — in the top 89% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Talis Biomedical Corporation (TLIS) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Talis Biomedical Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Talis Biomedical Corporation was 99.70%, occurring on Jul 14, 2025. The portfolio has not yet recovered.

The current Talis Biomedical Corporation drawdown is 99.32%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Talis Biomedical Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Talis Biomedical Corporation is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.